These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19179909)

  • 1. Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab.
    Tanvetyanon T; Murtagh R; Bepler G
    J Thorac Oncol; 2009 Feb; 4(2):268-9. PubMed ID: 19179909
    [No Abstract]   [Full Text] [Related]  

  • 2. Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy.
    Gore E; Currey A; Choong N
    J Thorac Oncol; 2009 Dec; 4(12):1590-1. PubMed ID: 20009916
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute renal failure in a patient receiving anti-VEGF therapy for advanced non-small cell lung cancer.
    Zhao J; Li H; Wang M
    J Thorac Oncol; 2009 Sep; 4(9):1185-7. PubMed ID: 19704343
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab in lung cancer: hurdles in clinical development.
    Pirker R
    Lancet Oncol; 2010 Aug; 11(8):703-4. PubMed ID: 20650687
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bevacizumab and arterial hypertension or proteinuria: management].
    Senellart H; Bennouna J
    Rev Mal Respir; 2008 Jun; 25(6):767-72. PubMed ID: 18772832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
    Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
    N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab safety in patients with central nervous system metastases.
    Besse B; Lasserre SF; Compton P; Huang J; Augustus S; Rohr UP
    Clin Cancer Res; 2010 Jan; 16(1):269-78. PubMed ID: 20028762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and tolerance of bevacizumab in non-small cell lung cancer: preliminary report].
    Mazières J; Dansin E
    Rev Pneumol Clin; 2008 Aug; 64(4):166-72. PubMed ID: 19019283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adverse events related to bevacizumab and the management principles in non-small cell lung cancer].
    Cheng G; Zhang L
    Zhongguo Fei Ai Za Zhi; 2010 Jun; 13(6):563-7. PubMed ID: 20681440
    [No Abstract]   [Full Text] [Related]  

  • 10. [Targeted therapies. New hopes, new challenges].
    Barlési F
    Rev Mal Respir; 2008 Jun; 25(6):661-2. PubMed ID: 18772823
    [No Abstract]   [Full Text] [Related]  

  • 11. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab.
    Katsenos S; Christophylakis C; Psathakis K
    Arch Bronconeumol; 2012 Jun; 48(6):218-9. PubMed ID: 22429334
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of bevacizumab for the treatment of non-small-cell lung cancer.
    Ramalingam S; Belani CP
    Future Oncol; 2007 Apr; 3(2):131-9. PubMed ID: 17381412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete regression of a non-small cell lung cancer choroidal metastasis with intravitreal bevacizumab.
    D'Antonio C; Viterbo A; Romiti A; Enrici MM; Lauro S; Marchetti P
    J Thorac Oncol; 2012 Feb; 7(2):468-9. PubMed ID: 22252564
    [No Abstract]   [Full Text] [Related]  

  • 15. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
    Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
    Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
    Klamerus JF; Brahmer JR
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esophageal fistula after EUS-FNA in a patient treated with bevacizumab for non-small-cell lung cancer.
    Stigt JA; Boomsma MF; de Vos tot Nederveen Cappel WH
    J Thorac Oncol; 2013 Mar; 8(3):e25-6. PubMed ID: 23407564
    [No Abstract]   [Full Text] [Related]  

  • 19. Implication of bevacizumab in fatal arterial thromboembolic incidents.
    Grivas AA; Trafalis DT; Athanassiou AE
    J BUON; 2009; 14(1):115-7. PubMed ID: 19365880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab.
    Gray J; Murren J; Sharma A; Kelley S; Detterbeck F; Bepler G
    J Thorac Oncol; 2007 Jun; 2(6):571-3. PubMed ID: 17545855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.